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ONLINE DATA SUPPLEMENT 
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SUPPLEMENTAL METHODS 
Cohort Characteristics 
All study visits were performed at National Referral Centre for Adult Cystic Fibrosis at St. 
Vincent’s University Hospital, Dublin, Ireland, where all subjects (people with CF and CFTR-
G551D mutations) received their routine CF care. Subjects’ median age was 29.5 years (range 
22-57), and 9 of 12 subjects were female.  Subjects manifested a range of lung dysfunction; 
FEV1 % predicted ranged from 34-101, with a mean FEV1 % predicted of 64.2.   
Written informed consent was obtained from all study participants following Research Ethics 
Committee approval. Inclusion criteria consisted of: age 18 years or older, clinical diagnosis of 
CF with the G551D-CFTR mutation on at least one allele (any known or unknown mutations 
allowed in second allele), stable clinical status with no significant changes in health status in the 
14 days prior to day 0 visit, and written informed consent. Subjects were excluded if they (a) 
participated in the VX-770 Extended Access Program or had used of ivacaftor within 6 months 
prior to the day 0 visit,  (b) exhibited any upper or lower respiratory symptoms requiring 
treatment with oral, inhaled or IV antibiotics within the 2 weeks prior to the day 0 visit, (c) had a 
history of solid organ transplantation, (d) pregnant or breast-feeding, or (e) exhibited the a 
condition or abnormality that in the opinion of the investigator would compromise the safety of 
the subject or the quality of the data. Subjects were allowed to continue standard therapy for CF 
except for treatments noted in the exclusion criteria described above. 
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All subjects began taking ivacaftor on March 4th, 5th or 8th, 2013, when ivacaftor became 
available in Ireland. At days 0, 2 and 7, each subject provided a spontaneously expectorated 
sputum sample and a blood sample, and underwent pulmonary function testing and sweat 
chloride testing. On day 0, subjects also underwent whole lung CT scanning. At later time points, 
only spontaneously expectorated sputum samples were obtained. Follow up pulmonary function 
testing was performed as part of subjects’ routine clinic care, and repeat CT scans were 
performed at 1 year of treatment on 7 subjects. Sputum specimens were obtained from all 8 P. 
aeruginosa-positive subjects at early time points, and at least 6 of the P. aeruginosa-positive 8 
subjects at each later time point. 
Sweat Chloride Measurements.  Sweat was collected with the Macroduct® collection system 
(Wescor, Logan UT), and sweat chloride levels were measured using routine standard laboratory 
techniques. 
Spirometry.  Spirometric measurements were obtained in accordance with the American 
Thoracic Society Standards (25). The forced expiratory volume in one second (FEV1) percent 
predicted values are based on the ECCS 1993 values for adults. 
Sputum processing for quantitation of bacterial density and inflammatory biomarkers, 
determination of microbiota relative abundance, and sputum proteomics. Sputum 
specimens were homogenized with cold 0.1% dithiotheitol (DTT). One aliquot of homogenized 
sputum was immediately frozen at -80oC. This specimen was later used for genomic DNA 
isolation, followed by quantitative PCR and total 16S rRNA gene sequencing (see below). A 
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second aliquot of homogenized sputum was serially diluted, and plated on MacConkey agar to 
quantify P. aeruginosa counts.  Homogenized sputum aliquots were also processed for 
quantification of sputum inflammatory markers (see below), and for mass spectroscopy to 
characterize sputum supernatant proteome (see below). 
Bacterial DNA extraction.  
DNA was extracted from DTT-treated sputum using the MO BIO PowerSoil DNA Isolation Kit 
with modifications to optimize DNA yield. Briefly; DTT-treated sputum was thawed on ice and 
homogenized for 30 seconds by repeated mixing using a 1 mL pipette. A 125 μi aliquot of the 
homogenate was transferred to a sterile 1.5 ml microfuge tube, to which 20 μa of lysozyme 
(final concentration 2.9mg/ml) and 20 μo of lysostaphin (final concentration of 0.14 mg/ml) 
were added. The specimen was mixed gently and incubated at 37°C for 30 minutes with gentle 
rocking. The mixture was then transferred to a sterile 2-ml screw cap tube containing 0.5 g of 
sterile DNA free zirconia/silica beads, 750 μ( of Power Bead lysis solution (MO BIO) and 60 
μs of solution C1 (MO BIO). The tube was incubated at 70°C for 10 minutes, then agitated at 
full speed for 90 seconds on a Mini-Beadbeater-16 (Biospec). All remaining steps were carried 
out as described by the manufacturer of the MO BIO PowerSoil DNA Isolation kit. The purified 
DNA sample was stored at -80°C.  
Real-time quantitative PCR.  
Quantitative PCR (qPCR) assays were used to quantify the total bacterial load (genome 
equivalents per gram of sputum (GE/g)), and the load (GE/g) of specific bacterial taxa in each 
sputum samples, including: P. aeruginosa, Prevotella spp., Streptococcus spp., and 
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Staphylococcus aureus. For P. aeruginosa, Prevotella spp., and S. aureus, probe-based 20 μr 
qPCR reactions included 10 µl of iTaq Universal Probes master-mix (Biorad), 300 nM of each 
primer/150nM of probe (appropriate for each specific assay), and 1 μL of template DNA; the 
remaining volume was made up with sterile nuclease-free water (see Table S16 for primer and 
probe sequences). The qPCR reaction was performed on a CFX96 Touch real-time PCR 
detection system (Biorad) using the reaction conditions as follows: initial incubation at 95ºC for 
4 min, followed by 39 cycles of 95ºC for 10 seconds and 60ºC for 1 m. Quantification of 
Streptococcus genera was carried out using the iTaq™ Universal SYBR® Green Supermix 
assay. The 20 μL qPCR reaction included 10 μr of iTaq™ Universal SYBR® Green Supermix, 
300nM of each primer (tuf), and 1 μM of DNA template; the remaining volume was reached 
using sterile nuclease-free water. The qPCR was performed on a CFX96 Touch real-time PCR 
detection system (Biorad). The reaction conditions were as follows: an initial incubation at 95ºC 
for 4 min, followed by 39 cycles of 95ºC for 10 seconds and 60ºC for 30 sec. 
Standard curves were generated for each qPCR assay by growing the type culture strain of the 
representative bacteria (Table S17), then isolating the DNA as described earlier. The DNA 
concentration for each sample was measured using the Qubit dsDNA assay kit (Life 
Technologies), using the DNA concentration and the mass of a single genome of the bacteria 
used for the standard curve the number of genome equivalents (GE) present in the extracted 
sample could be calculated. The DNA was serially diluted to create the standard curve for each 
qPCR assay. 
Bacterial 16S rRNA gene sequencing and analyses. 
E6 
The V3-V5 variable region of the 16S rRNA gene was amplified from each sample with primers 
containing Illumina adapter sequences, and a 12-bp index sequence for sample multiplexing 
(Table S18). Triplicate PCRs were performed for each sample in a total 25 μ. reaction volume 
containing 1x ThermoPol® reaction buffer (NEB), 10 μ  of each primer, 2.5U of taq DNA 
polymerase (NEB), 2 μD of DNA template and 18.5 μo of molecular grade water using the 
following reaction conditions: an initial incubation at 94°C for 5 minute followed by 30 cycles of  
94°C for 30 seconds, 55°C for 1 minute, and then 72°C for 1 m 30 seconds. After PCR the 
triplicate amplicons for each sample were pooled. Amplicon concentration of each pool was 
measured using the Qubit dsDNA assay kit (Life Technologies). Sequencing libraries for each 
sample were pooled in equal concentrations before sequencing for 600 cycles on an Illumina 
MiSeq desktop sequencer using the Miseq Reagent Kit v3. The 300 bp read 1 sequencing reads 
for each sample were de-multiplexed using the MiSeq Control Software. De-multiplexed 
sequencing reads were assigned to operational taxonomic units (OTUs) by UClust searching 
against the Silva rRNA gene database using Qiime (26, 27). Shannon alpha diversity was 
calculated using Qiime (27). 
Quantification of sputum inflammatory biomarkers.  Sputum was processed according to the 
CF Therapeutics Development Network Coordinating Center standard operating procedure. 
Briefly, DTT-treated aliquots of sputum were centrifuged at 250xg for 10 min at 4oC, pellets 
were recovered for proteomic analysis (see below), and supernatants were then centrifuged at 
4000xg for 20 min at 4oC. Supernatants from the second spin were either frozen directly at -80oC 
until analysis, or treated with protease inhibitor cocktail (Roche) and then frozen. Specimens 
were analyzed as previously described for interleukin (IL)-8, IL-6, and IL-1L [Luminex 
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Multiplex Bead, R&D Systems; Abingdon, Oxon, UK] and free neutrophil elastase (NE) activity 
[Spectrophotometric assay, Sigma Diagnostics; St. Louis, MO]. The lower limits of detection for 
these assays were: IL-6, 0.95 pg/ml; IL-8, 0.78 pg/mL; IL-1β, 0.34 pg/ml; free elastase , 0.25 
μg/mL. 
Proteomic Analysis of host proteins in sputum fractions. 
Proteome sample preparations: For sputum supernatant fractions, homogenized sputum was 
digested with Hyclone trypsin (1/10 volume dilution), incubated at 37oC for 20 minutes, and then 
centrifuged at 100xg for 10min at 4oC.  The supernatant from this slow spin was recovered and 
centrifuged at 10,000xg for 20min at 4oC. Supernatants recovered from the fast spin were frozen 
for proteomic analysis. 
Proteins were extracted from sputum samples with lysis buffer [100 mM Tris (pH 8.0), 4 % SDS, 
10 mM DTT].  Extraction mixtures were incubated at 95oC heat block for 5 min.  SDS was 
removed through buffer exchange with Amicon filters (10 KDa MWCO) (Millipore, Billerica, 
MA, USA) to urea buffer [50 mM NH4HCO3, 8 M Urea].  Proteins were alkylated, and digested 
sequencing grade Trypsin (Promega, Madison, WI, USA) overnight, using enzyme to substrate 
ratio (1:50, µg: µg).  Tryptic peptides were purified with C18 Sep-Pak columns (Waters, 
Milford, Mam USA), dried, and resuspended with 0.1% formic acid for LC-MS/MS analysis. 
LC-MS/MS analysis: Proteome samples were analyzed with a Q Exactive Plus mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) coupled to an EASY-nLC 1000 
system (Thermo Fisher Scientific).  Reversed-phase separation was performed with a 3 cm trap 
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column (packed in-house with 200 Å C18 magic bead, 5 µm) (Bruker, Billerica, MA, USA) and 
a 65 cm analytical column (100 Å C18 magic bead, 5 µm), using mobile phase of solvent A 
(0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile).  A linear separation 
gradient with 2%-10% solvent B for 1 min, 10%-30% solvent B for 89 min, and 30%-80% 
solvent B for 1 min was used.  The flow rate was set to 300 nL/min. 
Data dependent acquisition (DDA) analysis with Q Exactive Plus included MS (28) analysis with 
scan range 400-2000 m/z, scan resolution 70,000 and automatic gain control (AGC) target value 
1 × 106, and MS/MS analysis for the top 20 most abundant precursor ions detected in MS1 scans.  
MS/MS analysis included isolation window 1.6 m/z, fragmentation energy 25 NCE, scan 
resolution 17,500, AGC target value 5 × 104.  Charge exclusion for 1 + and unassigned ions was 
enabled.  Dynamic exclusion of 30 s was used. Each sputum sample was analyzed with three LC-
MS/MS replicate analyses. 
Proteome identification and quantitation: The raw data was converted to mzXML files with 
ReAdW (version 4.2.1).  The mzXML files were searched with Comet (28) (version 2015.01 
rev.02) against the concatenated database containing forward and reverse protein sequences of 
Human genome and Pseudomonas aeruginosa PAO1 genome (total of 56,798 entries, 
downloaded from Uniprot (29) on May 7, 2014).  Search parameters included 20 ppm precursor 
mass tolerance, 13C offsets (-1/0/1/2/3) enabled, fragment bin tolerance 0.1, fragment bin offset 
0, variable modifications of methionine oxidation (15.9949 Da), fixed modification of cysteine 
carbamidomethylation (57.021464 Da).  Only fully tryptic peptide sequences were considered, 
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and up to 2 missed cleavages were allowed.  The false discovery rate for peptide identification 
was determined with the target-decoy approach (30), and was controlled at 1%.   
Label-free quantitation for MS1 precursor ion intensity was performed with XPRESS (31).  
Peptide chromatograms (time, intensity) were used to determine peptide ratios.  Only peptides 
that were quantified in at least two technical replicates, and with Coefficient of Variation (CV) of 
chromatogram intensity < 80% in technical replicates were used for quantitative comparison to 
other samples.  The CV filtering process reduced the noise in peptide quantitation.  Peptide ratios 
quantified with different charge states were averaged to represent the peptide ratios.  The log2 of 
the peptide ratios were averaged to determine the log2 of protein ratios.  The protein fold 
changes were obtained with the anti-log2 transformation of log2 protein ratios.  
MLST analysis 
We collected 96 P. aeruginosa isolates that grew from day 0 sputum samples, and the latest time 
point available (between 90-975 days depending on the subject), pooled the DNA from each 
sample, and sequenced the pools using Illumina technology. Consensus sequences for each 
subjects’ isolates were generated (Fig S1) and then aligned to MLST sequences from the 
PubMLST Pseudomonas aeruginosa web site (http://pubmlst.org/ paeruginosa/) (14). Briefly,  
sequencing reads were mapped to set using BWA-MEM 0.7.13 (Li H. (2013) arXiv:1303.3997v1 
[q-bio.GN]). Indexing and initial variant calls for these alignments were then performed with 
SAMtools 1.3.1 and BCFtools 1.3.1 (32). Alignments and variant calls were further refined using 
Broad Genome Analysis Toolkit 3.5 per the GATK Best Practices Pipeline (33). Consensus 
MLST sequences were called using the GATK FastaAlternateReferenceMaker. These were then 
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aligned to all MLST alleles with NCBI Blast 2.2.31+ (34). MLST sequence types were assigned 
based on the most homologous sequence identity and bitscore values. Plotting of MLST results 
was done with matplotlib (35). 
High Resolution Computed Tomography 
The scanning protocol was based on the Spiromics study protocol and other previously published 
studies (36, 37).  Scans were preceded by three deep breaths to standardize lung volume history.  
Subjects were coached to reach TLC and RV.  These maneuvers were rehearsed prior to 
scanning.  All scans were performed as a helical acquisition at voltage of 120 kVp and tube 
current of 180 mA for inspiratory acquisition and tube current of 100 mA for expiratory 
acquisition on a GE HD750 CT scanner (General Electric Healthcare, USA). The slice thickness 
was 0.625 mm with an interval of 0.5 mm and a pitch of 0.984:1.  Scans were reconstructed with 
filtered back projection and standard kernel, and they were de-identified prior to transfer to the 
University of Washington for analysis. For scoring, the radiologists applied each of the 5 
parameters of the Brody score (bronchiectasis, peri-bronchial wall thickening, mucous plugging, 
parenchymal damage, and air trapping) to each of the 6 lobes of the lung (RUL, RML, RLL, 
LUL, Lingula, and LLL), and the sum of all scores was registered as the total Brody score. 
Statistical Analyses 
Bacterial, FEV1 and diversity index slopes were estimated via piece- wise mixed effects linear 
regression models with a random effect for each subject’s intercept and slope at study start and 
also immediately after initiating ivacaftor. These models included a fixed binary ‘treatment’ 
effect (pre versus post ivacaftor) that was tested within the confines of the model. An 
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unstructured correlation matrix was implemented, and means and 95% confidence intervals from 
the models were presented.  Similarly, piecewise linear models were used to estimate slopes 
between Day 0 and 210 and after the change point Day 210 to Day 975.  Tests for changes in 
slopes  at Day 210 were performed using two-sided, alpha=0.05 tests and mean slope estimates 
are reported with 95% confidence intervals.   
SUPPLEMENTARY FIGURE LEGENDS 
Figure S1. Multi-locus sequence typing of pooled P. aeruginosa isolates collected pre- and 
post ivacaftor. Ninety-six P. aeruginosa isolates were cultured from sputum samples collected 
at the indicated time points, isolates from each sample were pooled, and DNA from the pool was 
sequenced. Consensus sequence alignments were generated for each multi-locus sequence type 
(MLST) loci and the MLST type determined.  Each MLST loci is color coded (acs = grey, aro = 
blue, gua = red, mut = orange, nuo = green, pps = purple, trp = teal), with different shades 
indicating different alleles at that locus. The * indicates subjects in whom the acs loci showed 
ambiguity. 
Figure S2. Comparison of differences in population MLST allele frequency between before 
and after treatment P. aeruginosa pools from the same and different subjects. The percent 
change in MLST allele frequency (Y-axis) between two pools of isolates. Each position of the 
indicated MLST loci are represented on the X-axis. The left column shows differences in allele 
frequencies between pre- and post-ivacaftor pools of P. aeruginosa isolates from the same 
subjects. The right column shows differences in allele frequencies between pools of P. 
aeruginosa isolates from different subjects. Allele frequency changes were measured by 
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counting high-quality sequence read base alignments. To determine if there was a statistically 
significant difference in the change in allele frequency when comparing within-subject pools and 
between-subject pools, the following calculations were performed: the percent change at each 
base (if any) was summed for all MLST loci for each pair of pools. The results for each pair of 
pools were grouped into within-patient and between-patient categories, and these 2 categories 
were compared using the Students’ t-test to generate a p value.  
Figure S3.  Pulsed-field gel electrophoresis (PFGE) analysis of P. aeruginosa from Subjects 
4, 5, and 9 before ivacaftor after ivacaftor. The dendrogram indicating genetic similarity of the 
isolates is shown at the left portion of the figure and was generated using Bionumerics software 
with optimization and tolerance settings of 0.5% and 1.0%, respectively.  The source patient and 
day of isolate culture (“Isolate”) and the PFGE group number  (“Group”) are indicated next to 
each PFGE pattern.  Clonality is defined as isolates at least 90% genetically similar. The 
Salmonella serotype Braenderup H9812 PFGE pattern was used for gel-to-gel normalization. 
Figure S4.  Combined relative abundance of Streptococcus and Prevotella in sputum. 
Includes all available samples for subjects with chronic P. aeruginosa infections, and day 0-7 
samples for subjects without chronic P. aeruginosa infections. Values were calculated by 
summing the proportion of 16S rDNA reads mapping to Streptococcus and Prevotella at each 
time point.  Table S3 shows linear regression analysis using the mixed model which indicates 
that the slope of the combined relative abundance of Streptococcus and Prevotella species was 
positive in the first year (p=0.003), and exhibited a significant decrease in slope (p=0.008) 
thereafter.  
E13 
Figure S5.  Microbiota changes in the 4 study subjects not chronically-infected with P. 
aeruginosa.  A. Change in abundance of total bacteria as measured by quantitative PCR of 16S 
rDNA in sputum.  Red line shows the median values of all 12 subjects, the blue line shows the 
median value of the P. aeruginosa-negative subjects, and the black lines show values for 
individual P. aeruginosa-negative subjects.  B and C. Relative abundance of Burkholderia (B), 
and Staphylococcus species (C) during the first week of treatment. (B) shows the 2 subjects 
chronically infected with Burkholderia; and (C) shows the 4 subjects not infected with P. 
aeruginosa.  Sputum cultures performed by the clinical microbiology laboratory for the 4 
subjects shown in (C) were P. aeruginosa negative, and 3 of these subjects were Staphylococcus 
culture positive (by culture). D. Average changes in mean relative abundance of Pseudomonas, 
Burkholderia, and Staphylococcus sp. DNA in sputum of subjects in which each organism was 
detected. 
Figure S6.  Changes in sputum inflammation markers in the 4 study subjects not 
chronically-infected with P. aeruginosa. Changes in indicated inflammatory markers during the 
first week of ivacaftor treatment in the four patients without chronic P. aeruginosa infections. 
Red circles represent the average of all 12 patients (both the 8 P. aeruginosa positive and 4 P. 
aeruginosa negative patients). Blue circles represent the average of the 4 P. aeruginosa negative 
patients. White circles with black lines represent individual P. aeruginosa negative patients; 
*p<0.05.
Figure S1. 
Subject 
Day 
specimen 
collected 
Determined  
Allelic profile/ 
sequence type acs aro gua mut nuo pps trp 
1 0 1394 11/6 5 6 3 74 13 7 
975 1394 11/6 5 6 3 74 13 7 
2 0 1091 6 5 11 5 3 6 1 
975 1091 6 5 11 5 3 6 1 
4* 0 526 19/92 29 1 3 1 15 7 
975 526 25/22 29 1 3 1 15 7 
5* 0 526 19/92 29 1 3 1 15 7 
800 526 25/22 29 1 3 1 15 7 
6 0 167 40/11 5 11 5 4 38 37 
975 167 40/11 5 11 5 4 38 37 
7 0 395 148 5 1 1 1 12 1 
90 395 148 5 1 1 1 12 1 
9* 0 1068 23 5 11 7 1 12 137 
975 1068 125/11 5 11 7 1 12 137 
10 0 266 16 5 11 72 44 7 52 
975 266 16 5 11 72 44 7 52 
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* 
* 
* 
1 12/12 P. aeruginosa + 12/12 P. aeruginosa +
2 5/5 P. aeruginosa +
5/5 S. aureus +
12/12 P. aeruginosa +
4/12 S. aureus +
Intermittent S. aureus + cultures    
post-ivacaftor
3 12/12 S. aureus + 11/12 S. aureus +
4 4/4 P. aeruginosa + 3/3 P. aeruginosa + 
5 4/4 P. aeruginosa +
2/4 MRSA +
5/5 P. aeruginosa + Intermittent MRSA + cultures pre-
ivacaftor; none post
6 8/8 P. aeruginosa + 12/12 P. aeruginosa +
7 5/5 P. aeruginosa +
1/5 S. aureus +
None available Patient lost to follow up: no post-
ivacaftor clinical cultures
8 4/4 S. aureus + None available Patient lost to follow up: no post-
ivacaftor clinical cultures
9 14/14 P. aeruginosa + 13/13 P. aeruginosa + 
10 2/2 P. aeruginosa + 2/5 P. aeruginosa +
3/5 S. aureus +
P. aeruginosa negative in 2014 & 
2015, but  P. aeruginosa+ June 2016
11 5/5 B. multivorans +
5/5 S. aureus +
6/6 B. multivorans +
4/6  S. aureus +
1/6 P. aeruginosa +
P. aeruginosa + one time post-
ivacaftor; subsequent culture was P. 
aeruginosa  negative
12 2/2 B. multivorans + 2/2 B. multivorans +
2/2 S. aureus +
S. aureus detected post ivacaftor only
Table S1. Sputum microbiology data from clinical cultures
Patient
Sputum cultures
 2011 – March 2013
Sputum cultures 
March 2013 – June 2016 Notes
Estimate
Standard 
error p value*
95% 
confidence 
interval
Slope day 0 to 
210
-2.91 0.99 0.0046 -4.88 -
-0.93
Slope day 210 to 
975
0.082 0.35 0.82 -0.62 -
0.79
Change in slope 
at day 210
2.99 1.26 0.021 0.47 – 
5.52 
Table S2. Change in P. aeruginosa relative abundance and microbial diversity indices.
Estimate
Standard 
error p value*
95% 
confidence 
interval
Slope day 0 to 
210
2.47 0.62 0.0002 1.23 – 
3.70
Slope day 210 
to 975
-0.42 0.22 0.061 -0.86 –
0.021
Change in slope 
at day 210
-2.88 0.79 0.0005 -4.46 – 
-1.31 
Estimate
Standard 
error p value*
95% 
confidence 
interval
Slope day 0 to 
210
0.088 0.037 0.020 0.014 - 
0.16 
Slope day 210 to 
975
-0.015 0.013 0.28 -0.041 – 
0.012 
Change in slope 
at day 210
-0.10 0.047 0.034 -0.20 - 
-0.0081
Estimate
Standard 
error p value*
95% 
confidence 
interval
Slope day 0 to 
210
0.016 0.0085 0.059 -0.00064 -  
0.034  
Slope day 210 
to 975
-0.0026 0.0031 0.40 -0.0088 - 
0.0036  
Change in slope 
at day 210
-0.019 0.011 0.088 -0.041  -
0.0029  
P. aeruginosa relative abundance Richness
Shannon Diversity Evenness
*p values for slopes ( day 0 – 210, or day 210 – 975) indicate significant difference in slope as compared to a slope of 0 (no change in the 
parameter). p values for change in slope indicate a significant change in slope following day 210. 
Table S3. Change in relative abundance of Prevotella + Streptococcus
Estimate
Standard 
error p value*
95% 
confidenc
e interval
Slope day 0 to 
210
0.021 0.0067 0.0034 0.0072-
0.034
Slope day 210 to 
975
-0.0029 0.0024 0.22 -0.0077 -
0.0018
Change in slope 
at day 210
-0.024 0.0085 0.0079 -0.041 – 
-0.0065 
*p values for slopes ( day 0 – 210, or day 210 – 975) indicate 
significant difference in slope as compared to a slope of 0 (no 
change in the parameter). p values for change in slope indicate a 
significant change in slope following day 210. 
Subjects who presented 
for CT scans
(n = 7)
Subjects who did not 
present for CT scans
(n = 5)
p value
Number  P. aeruginosa +
(%)
5
(71%)
3
(60%)
0.72
Number male
(%)
1
(14%)
2
(40%)
0.40
Median age (years)
(range)
27
(22 – 35)
33
(25- 57)
0.22
Baseline sweat chloride (mM)
(± standard deviation)
94.8
(±14.7)
92.1
(± 20.3)
0.81
Mean % change in sweat chloride at day 
2 ivacaftor 
(± standard deviation)
56.6%
(±17)
49.0%
(±16.6)
0.46
Mean baseline FEV1 % predicted  
(± standard deviation)
57.7
(± 20)
73.4
(± 25)
0.28
Mean increase in % predicted  FEV1 at 
day 7 ivacaftor 
(± standard deviation) 
13
(± 8.6)
15
(± 8.6)
0.70
Table S4.  Demographic and disease characteristics of subjects who did and did not present for CT Scans.
Pre-ivacaftor
Mean
(Range)
1 year post-ivacaftor
Mean
(Range)
Mean change
(95% CI)
p value*
Total Brody Score 73.0
(43 –  134.5)
61.4
(20.5 – 122.5)
-11.6
(-25.5 − 2.3)
0.120
Bronchiectasis 20.8
(5.75 –  47.5)
18.7
(5 – 46.25)
-2.1
(-9.6 − 5.3)
0.762
Mucous Plugging 11.1
(6 – 16)
9.3
(4 – 16)
-1.9
(-2.9 − -0.8)
0.013
Peribronchial thickening 21.5
(12 – 44)
17.3
(6 – 37.75)
-4.2
(-10.0 − 1.5)
0.091
Parenchymal score 4.1
(0 – 11)
3.4
(1 – 8)
-0.7
(-3.4 − 2.0)
0.468
Hyperventilation/ air trapping 15.2
(2 -22.5)
12.1
(0 – 22.5)
-3.1
(-6.6 − 0.3)
0.130
* p values were calculated for log10 converted data, to account for wide spread of values and small cohort.
Table S5.  Changes in Brody scores of high-resolution CT scans after one year of ivacaftor (N = 7).
Decrease in sweat chloride 
between days 0 and 2
Decrease in sweat chloride 
between days 0 and 7
Fold decrease in P. aeruginosa at day 2 (CFUs) 0.524
0.183
8
0.393
0.383
7
Fold decrease in P. aeruginosa at day 7 (CFUs) 0.667
0.0710
8
0.429
0.337
7
Fold decrease in P. aeruginosa at day 2 (qPCR) 0.286
0.493
8
0.357
0.432
7
Fold decrease in P. aeruginosa at day 7 (qPCR) 0.595
0.120
8
0.536
0.215
7
Fold decrease in total bacteria at day 2 (qPCR) 0.441
0.152
12
0.627
0.0388
11
Fold decrease in total bacteria at day 7 (qPCR) 0.682
0.0208
12
0.733
0.0158
11
Table S6. Correlations between changes in sweat chloride at day 2 & 7 with reduction in microbiology at day 2 and 7. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Decrease in sweat chloride 
between days 0 and 2
Decrease in sweat chloride 
between days 0 and 7
Fold decrease in IL-1β at day 2 (Day 2/Day 0) -0.524
0.0800
12
0.100
0.770
11
Fold decrease in IL-1β at day 7 (Day 7/Day 0) 0.218
0.519
11
0.697
0.0251
10
Fold decrease in IL-8 at day 2 (Day 2/Day 0) -0.0699
0.829
12
0.309
0.355
11
Fold decrease in IL-8 at day 7 (Day 7/Day 0) 0.445
0.170
11
0.661
0.0376
10
Fold decrease in neutrophil elastase at day 2 (Day 2/Day 0) 0.497
0.101
12
0.545
0.0827
11
Fold decrease in neutrophil elastase at day 7 (Day 7/Day 0) 0.364
0.272
11
0.600
0.0667
10
Table S7. Correlations between changes in sweat chloride at day 2 & 7 with reduction in inflammatory parameters at day 2 
and 7. Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Absolute 
decrease in 
IL-1β at day 7
Fold 
decrease in 
IL-1β at day 7
Absolute 
decrease in 
IL-8 at day 7
Fold 
decrease in 
IL-8 at day 7
Absolute 
decrease in 
NE  at day 7
Fold 
decrease in 
NE at day 7
Log absolute 
decrease in 
P. aeruginosa 
at day 7 (CFU)
0.571
 0.180
7  
0.857
0.0137 
7
0.321
0.482
7
0.714
0.0713 
7
0.571
 0.180  
7
 0.750 
0.0522 
7
Log fold 
decrease in
 P. aeruginosa 
at day 7 (CFU)
0.595
0.120 
8 
0.619
0.102
8 
0.524
0.183
8
0.738
0.0366
8  
0.262
0.531 
8 
0.571 
0.139
8 
Log absolute 
decrease in P. 
aeruginosa at 
day 7 (qPCR)
0.679 
0.0938 
7
0.929
0.0025
7
0.500
0.253 
7
0.714
0.0713
7
0.786
0.0362
7
0.786
0.0362
7 
Log fold 
decrease in P. 
aeruginosa at 
day 7 (qPCR)
0.548
 0.160 
8
 0.571 
 0.139 
8
0.167 
0.693
8 
0.286
 0.493
8  
0.119
0.779
8  
0.286
0.493
8 
Log absolute 
decrease in 
total bacteria at 
day 7 (qPCR)
0.555
 0.0767
11 
0.618
 0.0426 
11
0.582
0.0604 
11
 0.691
 0.0186 
11 
0.682 
0.0208
11 
0.645
0.0320
11
Log fold 
decrease in 
total bacteria at 
day 7 (qPCR)
0.255 
0.450
11
0.409
0.212
11 
0.264
0.433
11
0.327
0.326
11
0.245
0.467 
11
0.264
0.433 
11
Table S8. Correlations between reduction in P. aeruginosa and total bacteria at day 7 with reduction in 
inflammatory markers at day 7.  Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Absolute 
increase in FEV1 Day 2
Absolute 
increase in FEV1  Day 7
Relative 
increase in FEV1 Day 2
Relative 
increase in FEV1  Day 7
Absolute increase 
in FEV1 % predicted 
Day 2
Absolute increase 
in FEV1 % predicted 
Day 7
Fold decrease in 
P. aeruginosa at day 2 
(CFUs)
-0.214
0.610
8
-0.0599
0.888
8
-0.500
0.207
8
-0.143
0.736
8
-0.132
0.756
8
-0.0362
0.932
8
Fold decrease in P. 
aeruginosa at day 2 
(qPCR)
-0.524
0.183
8
-0.0958
0.822
8
-0.619
0.102
8
-0.286
0.493
8
-0.419
0.301
8
-0.120
0.776
8
Fold decrease in total 
bacteria at day 2 
(qPCR)
-0.706
0.0102
12
-0.189
0.556
12
-0.792
0.0022
12
-0.399
0.199
12
-0.719
0.0084
12
-0.260
0.415
12
Decrease in 
P. aeruginosa relative 
abundance at day 2
-0.310
0.456
8
-0.850
0.0075
8
-0.190
0.651
8
-0.690
0.0580
8
-0.192
0.649
8
-0.880
0.0040
8
Fold decrease in 
P. aeruginosa at day 7 
(CFUs)
-0.405
0.320
8
-0.120
0.778
8
-0.571
0.139
8
-0.190
0.651
8
-0.419
0.301
8
-0.108
0.798
8
Fold decrease in
 P. aeruginosa at day 7 
(qPCR)
-0.524
0.183
8
-0.0240
0.955
8
-0.524
0.183
8
-0.262
0.531
8
-0.611
0.108
8
0.000
1.00
8
Fold decrease in total 
bacteria at day 7 
(qPCR)
-0.682
0.0208
11
-0.0592
0.863
11
-0.733
0.0102
11
-0.291
0.386
11
-0.836
0.0014
11
-0.128
0.708
11
Decrease in 
P. aeruginosa relative 
abundance at day 7
-0.357
0.385
8
-0.467
0.243
8
-0.429
0.289
8
-0.452
0.260
8
-0.443
0.272
8
-0.494
0.213
8
Table S9. Correlations between changes in microbiology parameters at day 2 & 7 with improvements in lung function at day 2 and 7.
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Absolute 
decrease in IL-1β 
at day 420
Fold 
decrease in IL-1β 
at day 420
Absolute 
decrease in IL-8 
at day 420
Fold 
decrease in IL-8
 at day 420
Absolute 
decrease in NE  
at day 420
Fold 
decrease in NE 
at day 420
Log absolute 
decrease in 
P. aeruginosa at 
day 7 (CFU)
 
0.300 
 0.624 
5
0.300 
 0.624 
5
-0.200
0.747  
5
0.200
0.747
5
0.500
0.391
5 
 0.900 
0.0374 
5
Log fold decrease 
in P. aeruginosa at 
day 7 (CFU)
0.600
 0.208 
6
0.314
 0.544
6 
0.543 
0.266
6
0.714
0.111 
6
0.257
0.623
6
0.657
 0.156  
6
Log P. aeruginosa 
counts (CFUs) at 
day 7
-0.429
0.397
6
0.200
0.704
6
-0.771
0.0724
6
-0.829
0.0416
6
0.200
0.704
6
0.0857
0.872
6
Log absolute 
decrease in 
P. aeruginosa at 
day 7 (qPCR)
 0.300
0.624
5 
0.700
 0.188 
5
0.300
0.624
5
-0.300
0.624 
5 
0.600
0.285
5
0.600
0.285
5
Log fold decrease 
in P. aeruginosa at 
day 7 (qPCR)
0.600
0.208 
6
0.314
0.544
6
 0.543
0.266 
6
0.714
0.111
6
0.257
0.623
6
0.657 
0.156
 6
Log P. aeruginosa 
counts (qPCR) at 
day 7
-0.429
0.397
6
-0.0286
0.957
6
-0.657
0.156
6
-0.829
0.0416
6
-0.0857
0.872
6
-0.371
0.469
6
Table S10. Correlations between reduction in P. aeruginosa at day 7 with reduction in inflammatory markers at day 420. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Absolute 
increase in FEV1 Day 0 - 420
Absolute 
increase in FEV1  Day 7- 420
Relative 
increase in FEV1 Day 0 - 420
Relative 
increase in FEV1  Day 7 - 420
Change in FEV1 slope
(L/month)
Change in 
FEV1 slope (% pred/month)
Fold decrease in 
P. aeruginosa at day 7 
(CFUs)
-0.286
0.493
8
-0.167
0.693
8
-0.381
0.352
8
-0.0476
0.911
8
-0.643
0.0856
8
-0.548
0.160
8
Fold decrease in 
P. aeruginosa at day 7 
(qPCR)
-0.262
0.531
8
-0.167
0.693
8
-0.333
0.420
8
-0.0952
0.823
8
-0.429
0.289
8
-0.310
0.456
8
Fold decrease in total 
bacteria at day 7 (qPCR)
-0.0636
0.853
11
0.000
1.00
11
-0.227
0.502
11
0.118
0.729
11
-0.155
0.650
11
-0.218
0.519
11
Decrease in 
P. aeruginosa relative 
abundance at day 7
-0.273
0.417
11
0.145
0.670
11
-0.0727
0.832
11
0.382
0.247
11
0.145
0.670
11
0.136
0.689
11
Absolute 
increase in FEV1 Day 0 - 420
Absolute 
increase in FEV1  Day 7- 420
Relative 
increase in FEV1 Day 0 - 420
Relative 
increase in FEV1  Day 7 - 420
Change in FEV1 slope
(L/month)
Change in 
FEV1 slope (% pred/month)
Fold decrease in 
P. aeruginosa at day 
420 (CFUs)
-0.0286
0.957
6
-0.0857
0.872
6
-0.143
0.787
6
-0.200
0.704
6
-0.943
0.0048
6
-0.771
0.0724
6
Fold decrease in 
P. aeruginosa at day 
420  (qPCR)
0.371
0.469
6
0.714
0.111
6
0.314
0.544
6
0.771
0.0724
6
-0.200
0.704
6
0.143
0.787
6
Fold decrease in total 
bacteria at day 420 
(qPCR)
0.257
0.623
6
0.200
0.704
6
-0.0857
0.872
6
0.543
0.266
6
0.0286
0.957
6
-0.0286
0.957
6
Decrease in
P. aeruginosa relative 
abundance at day 420
-0.257
0.623
6
0.143
0.787
6
-0.257
0.623
6
0.143
0.787
6
-0.714
0.111
6
-0.314
0.544
6
Table S11. Correlations between reduction in P. aeruginosa and total bacteria at day 420 with long term improvements in lung 
function. Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Table S12. Correlations between reduction in P. aeruginosa and total bacteria at day 7 with long term improvements in lung function. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1. 
Absolute 
decrease in 
IL-1β at day 420
Fold 
decrease in 
IL-1β at day 420
Absolute 
decrease in IL-8 
at day 420
Fold 
decrease in IL-8  
at day 420
Absolute 
decrease in NE  
at day 420
Fold 
decrease in NE 
at day 420
Log absolute 
decrease in total 
bacteria at day 7 
(qPCR)
-0.0857 
0.872
6
 0.143
0.787 
6
 -0.0286 
0.957
6
0.257
0.623
6
 -0.143 
 0.787
6 
0.429
0.397
6 
Log fold decrease 
in total bacteria at 
day 7 (qPCR)
0.257
0.623 
6
0.0286
 0.957
6 
0.371
0.469
6
0.600 
0.208
6
-0.200
0.704
6 
0.371
0.469 
6
Log total bacterial 
counts (qPCR) at 
day 7
-0.257
0.623
6
-0.0286
0.957
6
-0.771
 0.0724
6
-0.886
0.0188
6
0.143
0.787
6
-0.0857
0.872
6
	
	
Table S13. Correlations between reduction in total bacteria at day 7 with reduction in inflammatory markers at day 420. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Absolute 
increase in FEV1 Day 2
Absolute 
increase in FEV1  Day 7
Relative 
increase in FEV1 Day 2
Relative 
increase in FEV1  Day 7
Absolute 
increase in FEV1 % predicted 
Day 2
Absolute 
increase in FEV1 % predicted 
Day 7
Absolute change in 
richness 
between day 0 to 2
0.277
0.383
12
0.364
0.245
12
0.246
0.441
12
0.340
0.279
12
0.255
0.423
12
0.391
0.209
12
Absolute change in 
Shannon diversity 
between day 0 to 2
0.0769
0.812
12
0.676
0.0158
12
0.0771
0.812
12
0.643
0.0240
12
0.158
0.624
12
0.702
0.0110
12
Absolute change in 
evenness 
between day 0 to 2
-0.00699
0.983
12
0.673
0.0166
12
0.0315
0.923
12
0.678
0.0153
12
0.0807
0.803
12
0.684
0.0141
12
Absolute change in 
richness 
Between day 0 to 7
0.364
0.272
11
0.105
0.759
11
0.346
0.297
11
0.318
0.340
11
0.470
0.144
11
0.119
0.728
11
Absolute change in 
Shannon diversity 
between day 0 to 7 
0.136
0.689
11
0.506
0.113
11
0.342
0.304
11
0.736
0.0098
11
0.333
0.317
11
0.539
0.0872
11
Absolute change in 
evenness 
Between day 0 to 7 
0.0182
0.958
11
0.633
0.0365
11
0.205
0.545
11
0.773
0.0053
11
0.205
0.544
11
0.676
0.0225
11
Table S14. Correlations between improvements in FEV1 at days 2 and 7 with changes in diversity indices at days 2 and 7. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1. 
Absolute 
increase in FEV1 Day 0 - 420
Absolute 
increase in FEV1  Day 7- 420
Relative 
increase in FEV1 Day 0 - 420
Relative 
increase in FEV1  Day 7 - 420
Change in FEV1 slope
(L/month)
Change in 
FEV1 slope (% pred/month)
Absolute change in 
richness 
Between day 0 to 7
-0.227
0.502
11
-0.255
0.450
11
-0.0364
0.916
11
-0.145
0.670
11
0.0546
0.873
11
-0.0546
0.873
11
Absolute change in 
Shannon diversity 
between day 0 to 7 
0.0273
0.937
11
-0.245
0.467
11
0.164
0.631
11
-0.309
0.355
11
-0.218
0.519
11
-0.191
0.574
11
Absolute change in 
evenness 
Between day 0 to 7 
0.155
0.650
11
-0.218
0.519
11
0.164
0.631
11
-0.318
0.340
11
-0.309
0.355
11
-0.282
0.401
11
Absolute change in 
richness 
Between day 0 to 420
0.600
0.208
6
0.429
0.397
6
0.429
0.397
6
0.657
0.156
6
0.200
0.704
6
-0.0286
0.957
6
Absolute change in 
Shannon diversity 
between day 0 to 420 
0.314
0.544
6
-0.0857
0.872
6
0.200
0.704
6
0.143
0.787
6
0.429
0.397
6
-0.0857
0.872
6
Absolute change in 
evenness 
Between day 0 to 420
-0.0857
0.872
66
-0.486
0.329
6
-0.0857
0.872
6
-0.371
0.469
6
0.0857
0.872
6
-0.429
0.397
Table S15. Correlations between late and sustained improvements in FEV1 with changes in diversity indices at days 7 and 420. 
Top = R, Middle = p-value, bottom = n. Red  = p < 0.05, orange = p < 0.1.  
Target Gene Probe 
fluorophore
Directio
n
Sequence Amplicon 
Size (bp)
Reference
All bacteria 16S rRNA   Forward TCCTACGGGAGGCAGCAGT 466 Haarman
      Reverse GGACTACCAGGGTATCTAATCCTGTT    
    FAM Probe CGTATTACCGCGGCTGCTGGCA    
P. aeruginosa gyrB   Forward CCTGACCATCCGTCGCCACAAC 221 Le Gall
      Reverse CGCAGCAGGATGCCGACGCC    
    FAM Probe CCGTGGTGGTAGACCTGTTCCCAGACC    
Prevotella sp. 16S rRNA   Forward CCAGCCAAGTAGCGTGCA 151 Martin
      Reverse TGGACCTTCCGTATTACC    
    FAM Probe AATAAGGACCGGCTAATTCCGTGCCAG    
Streptococcus 
sp.
tuf^   Forward GTACAGTTGCTTCAGGACGTATC 196 Picard
    No probe Reverse ACGTTCGATTTCATCACGTTG    
S.aureus nuc   Forward GCGATTGATGGTGATACGGTT 270 Maes, Brakstad
      Reverse AGCCAAGCCTTGACGAACTAAAGC    
    FAM Probe GGTGTAGAGAAATATGGTCCTGAAGCAAGT    
^= SYBR Green Real-Time PCR assay
Table S16. Primers and probes for quantitative PCR assays
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               Bacterial taxa Strain ID
P. aeruginosa PA01
P. melaninogenica ATCC 25845
S. aureus NCTC 8325
S. parasanguinis ATCC 15911
S. salivarius ATCC 7073
Table S17. Bacterial taxa used in the construction of standard curves for taxa specific qPCR analysis. 
Primer name Purpose Sequence
Illumina-CCF PCR AATGATACGGCGACCACCGAGATCTACAC-TATGGTAATTGT-CCAGACTCCTACGGGAGGCAGC
                   Illumina adapter         Pad region           CCF universal forward primer
 
Illumina-
Id1-926R
PCR CAAGCAGAAGACGGCATACGAGAT-XXXXXXXXXXXX-AGTCAGTCAGCC-CCGTCAATTYYTTTRAGTTT
                   Illumina adapter             X Index X          Pad region          926R universal reverse primer
 
MiSeq-CCF sequencing TATGGTAATTGT-CCAGACTCCTACGGGAGGCAGC
        Pad region          CCF universal forward primer
 
MiSeq-926R sequencing AGTCAGTCAGCC-CCGTCAATTYYTTTRAGTTT
        Pad region           CCF universal forward primer
 
MiSeq-926R-
Index
sequencing AAACTYAAARRAATTGACGGGGCTGACTGACT
Table S18. Primers used for microbiota 16S rRNA library construction and sequencing 
